Display options
Cite
de Beauchamp L, Baquero P, Kuntz EM, et al. Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells". Mol Cell Oncol. 2017;5(1):e1403532doi: 10.1080/23723556.2017.1403532.
de Beauchamp, L., Baquero, P., Kuntz, E. M., Gottlieb, E., & Helgason, G. V. (2018). Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells". Molecular & cellular oncology, 5(1), e1403532. https://doi.org/10.1080/23723556.2017.1403532
de Beauchamp, Lucie, et al. "Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells"." Molecular & cellular oncology vol. 5,1 (2018): e1403532. doi: https://doi.org/10.1080/23723556.2017.1403532
de Beauchamp L, Baquero P, Kuntz EM, Gottlieb E, Helgason GV. Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells". Mol Cell Oncol. 2017 Dec 18;5(1):e1403532. doi: 10.1080/23723556.2017.1403532. eCollection 2018. PMID: 29404396; PMCID: PMC5791851.
Copy Download .nbib Format: NLM
Share it on

Mol Cell Oncol. 2017 Dec 18;5(1):e1403532. doi: 10.1080/23723556.2017.1403532. eCollection 2018.

Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells".

Molecular & cellular oncology

Lucie de Beauchamp, Pablo Baquero, Elodie M Kuntz, Eyal Gottlieb, G Vignir Helgason

Affiliations

  1. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow UK.
  2. Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow, UK.
  3. Technion Integrated Cancer Center, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.

PMID: 29404396 PMCID: PMC5791851 DOI: 10.1080/23723556.2017.1403532

Abstract

We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

Keywords: CML; Cancer stem cells; Imatinib; Leukaemia; Metabolism; OXPHOS; TCA cycle; Tigecycline; Tyrosine kinase inhibitor

References

  1. Nat Med. 2017 Jun;23 (6):692-702 - PubMed
  2. Cancer Med. 2016 Nov;5(11):3031-3040 - PubMed
  3. Nature. 2015 Sep 17;525(7569):380-3 - PubMed
  4. Cancer Cell. 2011 Nov 15;20(5):674-88 - PubMed
  5. Blood. 2017 Mar 23;129(12 ):1595-1606 - PubMed
  6. Cancer Discov. 2016 Nov;6(11):1248-1257 - PubMed
  7. Nature. 2016 Jun 08;534(7607):341-6 - PubMed
  8. Blood. 2013 May 16;121(20):4175-83 - PubMed
  9. Nat Med. 2017 Oct;23 (10 ):1234-1240 - PubMed
  10. Cell Stem Cell. 2013 Mar 7;12(3):329-41 - PubMed

Publication Types